Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders for Inhibikase Therapeutics, Inc., held on June 25, 2021. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Atlanta, Georgia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Two proposals were approved by stockholders at the Annual Meeting:
- Proposal One (Director Election): Milton H. Werner, Ph.D., was elected as a Class I director to serve until the 2024 annual meeting.
- Total Votes For: 6,172,090
- Total Votes Withheld: 25,573
- Total Broker Non-Votes: 720,818
- Proposal Two (Auditor Ratification): The appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.
- Total Votes For: 6,892,719
- Total Votes Against: 3,591
- Total Votes Abstain: 22,171
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the stockholder vote.
Key Facts for Investor Verification
- Milton H. Werner, Ph.D., was elected to the Board of Directors for a term ending in 2024.
- CohnReznick LLP was ratified as the independent auditor for the 2021 fiscal year.
- A significant number of broker non-votes (720,818) were recorded for the director election, though this did not affect the outcome.
- The Company is classified as an emerging growth company.